You are here: Home » News-IANS » Health-Medicine
Business Standard

Sale of anti-diabetic medicines shoots up in India

IANS  |  New Delhi 

Sales of anti-diabetic medicines, including insulin, has zoomed in India, along with the steadily increasing number of diabetics, says a study.

The findings led by Anoop Misra, Chairman at Fortis C-DOC Hospital, showed that from Rs 151.2 crore in 2008, the sale of insulin (especially newer insulin) rose to Rs 842 crore in 2016.

Sales of oral drug (especially newer ones) also went up from Rs 278.5 crores in 2013 to Rs 700 crore in 2016.

The spike could be attributed to the rising number of patients, increased availability and aggressive marketing by pharmaceutical companies.

On the other hand, the affordability and accessibility of the anti-diabetic therapy to lower socio-economic strata remained inadequate, the study said.

"Increasing sales of high cost medications as shown by our data are particularly worrisome since most Indians pay out of their pocket and nearly seven per cent experience catastrophic expenditure for diabetes," Misra said.

According to the World Health Organization (WHO), the number of adults suffering from diabetes has risen from 4.7 per cent of the global population in 1980 to 8.5 per cent in 2014.

In 2015, the disease touted as lifestyle epidemic affected 415 million people worldwide while there were 69.1 million people with diabetes in India -- the second highest in the world after China, which had 109 million people, according to the report "Diabetes Atlas" released by the International Diabetes Federation (IDF).

"India has to take several stringent measures to ensure that there is a balancing mechanism in place, education of physicians, tighter regulations on price control and stricter norms for pharmaceutical companies around new drugs and marketing ethics," Misra added.

The research was based on the data of sales trends from all top selling drugs (20 brands) for the past nine years (between December 2008 and December 2016), with emphasis on anti-diabetic drugs.



(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Mon, November 13 2017. 19:30 IST